UPDATE 2-Biogen delays Alzheimer's drug filing plans, shares fall 11%

Biogen Inc on Wednesday delayed the filing for marketing approval of its experimental Alzheimer's disease drug, saying that it needed more time to prepare the data before submission.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.